Transient diabetes insipidus in critically ill COVID19 patients
Authors' conclusion
Temporary DI prevalence after vasopressin discontinuation in COVID19 ECMO patients might be higher than previously described for vasopressin-treated patients.
Study context
- Population
- COVID19 patients on ECMO (July 6, 2020, to November 30, 2021)
- Participants
- 37 patients · 18 diabetes insipidus (DI) episodes
- Exposure
- Patients who developed DI vs those who did not
- DIn = 12
- Outcome
- Transient DI
Methodological detailscase series
- Case series
Main finding
As reported in the abstract
- Patients with DI
- 12
- DI episodes
- 18
- Episodes after vasopressin discontinuation
- 17
- Episodes treated with vasopressin reinstitution
- 14
- DI duration, median
- 21 h
- Sodium increase, median
- 14 mEq/L
Observational data: associations, not effects.
Further findings
Baseline characteristics and mortality, DI vs no DI
- DI patients 7 years younger
- 7
- Lower severity scores (APACHE-II and SOFA) in DI patients
- No mortality difference between groups
Original publication
Transient diabetes insipidus in critically ill COVID19 patients. J Crit Care. Published 9 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →